Moleculin Completes Enrollment in Pivotal AML Trial, Data Readout on Track for Q1 2027
MBRX has more than doubled off its 52-week low of $0.161.
Summary
Moleculin has completed enrollment in Part A of its Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML, with 89 subjects enrolled and one in screening. The company reaffirmed the comprehensive Part A data readout for Q1 2027. Management highlighted a shift in patient composition toward a 50/50 fit/unfit split versus 70/30 in the first 45 subjects, which may make efficacy harder to demonstrate but provides broader insight. This milestone follows the July interim data showing 37% blinded CRc and the recent $9.3M offering at $0.75. The company remains under Nasdaq delisting pressure and going concern doubts, so the Q1 2027 readout is a critical binary event.
Updates
· SEC 8-K — The 8-K attaches the press release and abstract as Exhibits 99.1 and 99.2.
At the time of this announcement, MBRX was trading at $0.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6M. The 52-week trading range was $0.16 to $15.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.